Loading...
PT-141
Add to Wishlist
Melanocortin Receptor Agonist — Neuroendocrine Research Compound
In Stock
10mg
$60.00$72.00
You Save
$12.00In Stock — Ships Same Day
Includes
10mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist derived from the alpha-MSH analog Melanotan II, with selective activity at MC3R and MC4R receptors in the hypothalamus and limbic system. Unlike vascular-acting compounds such as PDE5 inhibitors or alprostadil, PT-141 operates entirely through the central nervous system — activating MC4R on hypothalamic paraventricular nucleus neurons to initiate downstream signaling through oxytocin and dopamine pathways that modulate sexual desire and arousal at the neurological level. The FDA approved bremelanotide (Vyleesi) in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first centrally-acting agent approved for this indication. Clinical trials demonstrated that PT-141 significantly increased sexual desire, arousal, and satisfying sexual events compared to placebo in both female and male subjects across multiple Phase 2 and Phase 3 studies published in the Journal of Sexual Medicine. What distinguishes PT-141 from all other sexual health compounds is its mechanism — it enhances desire rather than simply enabling mechanical function, addressing the neurological component of sexual response that vascular agents cannot reach. This PEPCELL product is a research-grade compound for laboratory investigation, not the FDA-approved Vyleesi pharmaceutical product.
Handling & Storage
Published research protocols reference subcutaneous administration. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference 1.75mg subcutaneous doses. Consult applicable literature for specific research applications.
Research Applications
Central Mechanism
Activates MC4R receptors on hypothalamic paraventricular nucleus neurons, triggering downstream oxytocin and dopamine signaling cascades that modulate sexual desire and arousal. This central nervous system mechanism is fundamentally distinct from PDE5 inhibitors (vascular cGMP) and alprostadil (vascular cAMP), which act on peripheral blood vessel smooth muscle without affecting desire.
Initial effects within first month
Research Studies
Desire Enhancement
Increases sexual desire, arousal, and satisfying sexual events through neurological activation rather than mechanical vascular effects. Phase 3 clinical trials (RECONNECT) demonstrated statistically significant increases in desire domain scores and reductions in distress associated with low sexual desire. PT-141 is the only compound class that directly addresses the desire component of sexual response.
Initial effects within first month
Research Studies
Gender-Inclusive
Clinical research has demonstrated efficacy in both male and female subjects, as the melanocortin MC4R pathway governs sexual arousal and desire across sexes. The FDA approved bremelanotide (Vyleesi) for premenopausal women with HSDD in 2019, while earlier Phase 2 studies in men showed significant improvements in erectile function through this same central pathway.
Initial effects within first month
Research Studies
Frequently Asked Questions
How does this PT-141 relate to the FDA-approved Vyleesi?
PT-141 (bremelanotide) is the same active peptide in the FDA-approved product Vyleesi, which was approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. However, this PEPCELL product is a research-grade compound manufactured for laboratory investigation and is not the Vyleesi pharmaceutical product. Individuals seeking bremelanotide for medical use should consult a physician.
How does PT-141 differ from Viagra/sildenafil?
PT-141 works through central nervous system MC4R melanocortin receptors to enhance sexual desire and arousal at the neurological level. Sildenafil (Viagra) inhibits PDE5 enzyme in penile blood vessels to maintain erections by preventing cGMP breakdown. These are completely different mechanisms — PT-141 affects desire (wanting), while PDE5 inhibitors affect mechanical vascular function (ability). They address different components of sexual response.
How should PT-141 be reconstituted and stored?
Reconstitute lyophilized PT-141 with bacteriostatic water by slowly injecting along the vial wall. The cyclic heptapeptide structure provides good stability in solution. Store unreconstituted peptide at -20°C. After reconstitution, refrigerate at 2-8°C and use within 30 days.
What purity testing does PEPCELL perform on PT-141?
Each PT-141 batch undergoes independent HPLC purity analysis and mass spectrometry identity verification at Janoshik Analytical Laboratory, confirming both purity and correct cyclic peptide structure. Current batches test at 99.1% purity with batch-specific Certificates of Analysis provided.
Is PT-141 intended for human use?
This research-grade PT-141 (bremelanotide) is sold exclusively for in-vitro research, melanocortin receptor studies, and laboratory investigation. While bremelanotide is FDA-approved as Vyleesi for a specific clinical indication, this PEPCELL product is not manufactured to pharmaceutical standards and is not intended for human consumption or self-administration.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
Research Articles
Published research and educational content related to PT-141
Research14 min read
Immune-Modulating Peptides: Thymosin Alpha-1, LL-37, and KPV Research
An overview of three key peptides being studied for their immune-modulating properties, covering innate and adaptive immune mechanisms, published research findings, and the current state of immunopeptide science.
Michael TorresContent Director
Research11 min read
BPC-157 vs TB-500: Comparing Recovery Research Peptides
A detailed comparison of two of the most studied recovery peptides in preclinical research, examining their distinct mechanisms, published findings, and how investigators approach studying them individually and in combination.
Dr. Sarah ChenChief Science Officer
Guides11 min read
The Complete Guide to Peptide Reconstitution for Research
A step-by-step guide to reconstituting lyophilized research peptides, covering solvent selection, concentration calculations, proper technique, post-reconstitution storage, and common mistakes to avoid.
Michael TorresContent Director
Education14 min read
A Beginner's Guide to Peptides: What They Are and How They Work
New to the world of peptides? This guide covers the fundamentals of peptide science, their biological roles, and why they have become a focus of modern wellness research.
Michael TorresContent Director